Research Creative   My Account   Submit My Manuscript
Letpub, Scientific Editing Services, Manuscript Editing Service

Scientific Journal Selector



OncoTargets and Therapy


👁  219104 Views

 1245 Reviews  

 Open Access      SCIE      Official Website     Submission Website
Return to Search
 

*Average Peer Review
Slow, 6-12 Week(s)
*Competitiveness
Moderate
CiteScore
9.7

CiteScore Rank
Subject Area Rank Percentile
Category: Medicine
Subcategory: Pharmacology (medical)
23 / 272
91%
Category: Medicine
Subcategory: Oncology
65 / 404
84%



Country/Area of Publication
ENGLAND
Publication Frequency
Publisher
Dove Medical Press Ltd.

ISSN
1178-6930
E-ISSN
Year Publication Started
2008

Self-citation (2023-2024)
0.00%
Annual Article Volume
75
Gold OA Percentage
96.46%


Open Access Info
APC APC Waiver Other Charges
Yes: Check details
( USD2990; )
Yes: Check detailsNo

Journal Aim & Scope
OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer.

The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype.

Specific topics covered by the journal include:

-Novel therapeutic targets and innovative agents
-Novel therapeutic regimens for improved benefit and/or decreased side effects
-Early stage clinical trials

Further considerations when submitting to OncoTargets and Therapy:

-Studies containing in vivo animal model data will be considered favorably.
-Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines.
-Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples.
-Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.
-Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.
-Single nucleotide polymorphism (SNP) studies will not be considered.


Web of Science Quartiles
WOS Quartile: Q3

Quartiles By JIFCollectionQuartileRankPercentage
Category: BIOTECHNOLOGY & APPLIED MICROBIOLOGYSCIEQ390/174
48.6%
Category: ONCOLOGYSCIEQ3163/322
49.5%
Quartiles By JCICollectionQuartileRankPercentage
Category: BIOTECHNOLOGY & APPLIED MICROBIOLOGYSCIEQ273/174
58.33%
Category: ONCOLOGYSCIEQ2135/322
58.23%
*Crowdsourced data
  • Journals In The Same Subject Area
  • CiteScore Trends
  • Self Citation Trends
  • Annual Article Volume Trends
  • Journal Title h-index CiteScore
    Nature Cancer031.10
    JAMA Oncology4137.50
    JAMA Oncology6137.50
    Trends in Cancer028.50
    Liver Cancer2520.80
    Experimental Hematology & Oncology012.60
    ESMO Open011.70
    Cancer Biology & Medicine299.80
    Annual Review of Cancer Biology014.50
    Cancers538.00
  • OncoTargets and Therapy OncoTargets and Therapy
    Predict CiteScore Trend:
    Steady Increase No Change Gradual Decline  Refresh
 
    👁  219104 Views
      1245 Reviews        
 
 
 

Select your rating and start your review of OncoTargets and Therapy

 

    可歆三岁啦
    Status: N/A

    2024-07-17

    Seriously, the review fee or page fee is $3000, which instantly discourages me.




    法慧世暄
    Status: N/A

    2024-05-12

    Excuse me, how long has it been since 2a?




    一只素芬呀
    Status: N/A

    2024-03-28

    Regrettably~~~~~~Our出版政策规定,每篇手稿必须至少有两组同行审稿意见,以便编辑决策者能够对手稿做出结论。不幸的是,尽管我们经过多周的努力,仍未能获得您手稿所需的审稿人数。为了不进一步延迟您的手稿,主编决定拒绝您的手稿,以便您可以与其他出版商联系,他们可能更能找到合适的审稿人




    一只素芬呀
    Status: N/A

    2024-02-22

    1. We started inviting reviewers on the 7th. 2. We only invited one on the 4th, and as of the 23rd, we have not yet invited a second. The journal requires at least two reviewers, and we are unsure how long it will take




    一只素芬呀
    Status: N/A

    2024-02-22

    You can remind them, I have reminded them before and they responded quite promptly, but the progress did not speed up




    明冠文柏
    Status: N/A

    2024-02-01

    It's been a month already, and I'm still in 1A. Does this mean I have no chance? Should I send a reminder?




    明冠文柏
    Status: N/A

    2024-01-31

    Review speed: 2.0 Experience sharing: 1A It has been a month, is there still hope, do I need to urge for review?




    一只素芬呀
    Status: N/A

    2024-01-23

    It has been two weeks, can't find reviewers? Should we remind the editor?




    天罡和通
    Status: N/A

    2023-12-21

    I want to ask what does 7f mean in this magazine?




    回风嘉蕊
    Status: N/A

    2023-10-08

    It's been almost two weeks for me




Journals In The Same Field
CA-A CANCER JOURNAL FOR CLINICIANS
CiteScore: 873.20

LANCET
CiteScore: 148.10

NEW ENGLAND JOURNAL OF MEDICINE
CiteScore: 145.40

NATURE REVIEWS DRUG DISCOVERY
CiteScore: 137.40

NATURE REVIEWS CANCER
CiteScore: 111.90

NATURE MEDICINE
CiteScore: 100.90

Nature Reviews Clinical Oncology
CiteScore: 99.40

NATURE REVIEWS IMMUNOLOGY
CiteScore: 93.40

Lancet Respiratory Medicine
CiteScore: 87.10

Nature Reviews Disease Primers
CiteScore: 76.70



© 2010-2025  ACCDON LLC 400 5th Ave, Suite 530, Waltham, MA 02451, USA
PrivacyTerms of Servic